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Abstract
Approximately 75% of patients with late-stage breast cancer will develop bone 
metastasis. This condition is currently considered incurable and patients’ life expectancy 
is limited to 2–3 years following diagnosis of bone involvement. Interleukin (IL)-1B is a 
pro-inflammatory cytokine whose expression in primary tumours has been identified as a 
potential biomarker for predicting breast cancer patients at increased risk for developing 
bone metastasis. In this review, we discuss how IL-1B from both the tumour cells and the 
tumour microenvironment influence growth of primary breast tumours, dissemination 
into the bone metastatic niche and proliferation into overt metastases. Recent evidence 
indicates that targeting IL-1B signalling may provide promising new treatments that can 
hold tumour cells in a dormant state within bone thus preventing formation of overt 
bone metastases.
Introduction
Breast cancer bone metastasis is an incurable disease. 
Breast cancer is the most common cause of cancer death 
in females in Europe and worldwide. Although the 
mortality rate decreased by 35% since the early 1970s, it 
is estimated that one in eight females will develop breast 
cancer during their lifetime and the incidence rate is 
expected to increase by 2% in the United Kingdom by 
2035 (Cancer Research UK, Cancer Statistics, July 2017).
Bone is the most common metastatic site for breast 
cancer, and bone metastases are associated with poor 
prognosis and significantly reduced life expectancy to 
just 2–3  years following diagnosis. Patients with bone 
metastasis experience increased morbidity due to severe 
pain, reduced mobility, hypercalcemia, osteolysis and 
bone fractures, as well as spinal cord compression and 
bone marrow aplasia. Bone pain is generally due to 
mechanical pressure exerted by a tumour cell mass or 
due to the release of inflammatory cytokines by either 
the tumour cells themselves or by the surrounding bone 
microenvironment, leading to altered bone homeostasis 
(Macedo et al. 2017).
The formation of breast cancer metastases in bone 
generally occurs in the axial skeleton, possibly in relation 
to high bone marrow content, where haematopoiesis 
actively takes place. The microenvironment is 
fundamental in attracting tumour cells to bone as well 
as promoting tumour progression. The composition of 
the tumour microenvironment changes during tumour 
development and is different at different sites (Hanahan 
& Weinberg 2011). This variation differently affects cancer 
progression as well as the efficacy of therapeutic regimes. 
A plethora of signalling molecules is involved in the 
intricate network of signalling pathways that orchestrate 
the communication between cancer cells and surrounding 
stroma. Interleukin-1B (IL-1B) is a pro-inflammatory 
cytokine whose expression in primary tumours has been 
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identified as a potential biomarker for predicting breast 
cancer patients at increased risk for developing bone 
metastasis (Nutter et al. 2014).
Here, we provide a detailed overview of the 
molecular mechanisms underlying primary breast cancer 
development and formation of metastasis in bone, 
reporting recent evidence that suggest a pivotal role of 
IL-1B in these processes. Finally, we summarise current 
therapies that target the IL-1 signalling pathway that 
have the potential to be repurposed for the treatment of 
metastatic breast cancer.
Breast cancer bone metastasis and the 
bone microenvironment
The bone is a preferred metastatic site for breast cancer 
cells. When tumour cells home to the bone, they utilise 
molecular mechanisms that control the interaction 
between different cell types including osteoblasts, 
osteoclasts and haematopoietic stem cells, altering bone 
homeostasis to promote tumour cell survival, dormancy 
and/or proliferation in this environment (Mishra  et  al. 
2011). In bone, the bone marrow is the main site of 
haematopoiesis. Because haematopoetic stem cell (HSC) 
self-renewal and haematopoietic progenitor proliferation, 
commitment and differentiation occur in the same 
microenvironment, it is suggested that there must be 
different specific niches composed by different stromal 
cells that can regulate each step from HSC renewal to 
complete differentiation (Cordeiro-Spinetti  et  al. 2015). 
The bone marrow cavity can be divided into four niches: 
endosteal, subendosteal, central and perisinusoidal 
(Lord  et  al. 1975, Lambertsen & Weiss 1984). HSC and 
multipotent progenitors are found in the endosteal and 
subendosteal regions, whereas committed progenitors 
are located in the central region and the differentiated 
cells in the perisinusoidal niche (Cordeiro-Spinetti et al. 
2015). Tumour cells home to specific regions in bone. It 
has been suggested that the bone microenvironment is 
a dynamic niche and that the formation of metastatic 
lesions resembles a constant osteogenesis process, 
allowing early-stage bone colonization. During this 
process, adherens junctions form between metastatic 
tumour cells, expressing E-cadherin, and cells in the bone 
niche, specifically osteogenic cells, expressing N-cadherin 
(Wang  et  al. 2015). It is hypothesised that tumour cells 
either remain dormant or are stimulated to proliferate into 
overt metastases dependent on which niches they interact 
with: Interactions between CXCR4, found on metastatic 
tumour cells, and CXCL12, expressed by osteoblasts, 
mesenchymal stem cells (MSCs) and adventitial reticular 
cells (Sugiyama et al. 2006) are a key component in homing 
and adhesion of tumour cells to the bone metastatic niche. 
In the endosteal niche, tumour cells are thought to be held 
in a quiescent state through CXCR4/CXCL12 interactions 
using similar mechanisms to those used by osteoblasts to 
maintain quiescence of HSCs (Wang et al. 2014). Tumour 
cells hijack mechanisms of HSCs mobilization and 
proliferation and form overt metastasis (Ottewell 2016). 
In addition, the role of CXCL12 in the primary tumour 
in the establishment of organ-specific metastasis has been 
described: Cancer-associated fibroblasts in the primary 
tumour mimic the bone marrow microenvironment by 
producing CXCL12, which has been found to enrich 
breast cancer Src-hyperactive clones, which survive in the 
bone marrow (Zhang  et  al. 2013). Src is responsible for 
mediating breast cancer cell survival in the bone marrow, 
by controlling tumour cell response to both pro-survival 
signals in the bone microenvironment like CXCL12 and 
by conferring resistance to pro-apoptotic signals such as 
TRAIL (Zhang et al. 2009).
Breast cancer metastasis primarily manifests as a bone 
lytic disease; however, osteolytic, osteoblastic and mixed 
lesions occur. In the case of osteolytic metastases, tumour 
cells stimulate osteoclast activity and/or inhibit osteoblast 
differentiation, leading to increased bone resorption 
and/or decreased bone formation, respectively, finally 
resulting in the development of bone disease and higher 
risk of fractures. A vicious cycle between breast cancer 
cells and bone occurs and sustains the growth of tumour 
metastases. Growth factors, produced by osteoblasts, bind 
the bone matrix. Upon osteoclast-mediated resorption, 
growth factors are released into the local environment 
where they stimulate tumour cell growth. In turn, cancer 
cells themselves alter the function of both osteoblasts 
and osteoclasts, affecting bone turnover (Ottewell 2016) 
(Fig.  1). Molecules released by osteoblasts, osteoclasts 
and tumour cells during bone turnover have been 
extensively reviewed in (Weilbaecher  et  al. 2011, Le 
Pape  et  al. 2016, Ottewell 2016) and shown in Fig.  1. 
IL-1B plays a role in bone homeostasis. Inhibition of 
IL-1B prevents osteoclastogenesis and osteoblastogenesis, 
thus impairing bone resorption and bone formation, 
respectively (Nakamura & Jimi 2006, Ruscitti et al. 2015). 
IL-1B was shown to be produced by peripheral blood 
mononuclear cells (PBMCs) in premenopausal women 
who underwent ovariectomy and experienced a decrease 
in bone mineral density. Oestrogen administration 
restored IL-1B levels in these patients, thus suggesting 
that IL-1B has a major role in bone resorption upon 
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oestrogen withdrawal (Pacifici et al. 1991). In osteoblastic 
metastases, tumour cells support osteoblastogenesis and 
osteoblast stimulation. In particular, transforming growth 
factor β (TGFB), bone morphogenetic proteins (BMPs) 
and WNT proteins are known to activate transcription 
factors, like RUNX2, that control osteoblast function. 
It is thought that metastatic tumour cells release such 
factors that drive osteoblast formation (Weilbaecher et al. 
2011). Once activated, osteoblasts produce factors such 
as interleukin-6 (IL6), monocyte chemotactic protein-1 
(MCP-1), vascular endothelial growth factor (VEGF) 
and macrophage inflammatory protein-2 (MIP-2) that 
sustain cancer growth and interaction with other cells 
in the bone microenvironment. Production of CXCL12, 
BMPs and Notch by osteoblasts sustains the recruitment 
of tumour cells in a similar manner to the physiological 
HSCs recruitment (Weilbaecher et al. 2011). In osteolytic 
metastases, TGFB and receptor activator of nuclear factor 
kappa-B ligand (RANKL) play a major role in driving 
tumour-bone vicious cycle, whereas BMP, epidermal 
growth factor (EGF) and platelet-derived growth factor 
(PDGF) signalling have been found to support this cycle 
in osteoblastic metastases (Ottewell 2016).
The formation of osteolytic lesions has been 
associated with extracellular matrix-modifying enzymes, 
lysyl oxidases (LOXs). In particular, LOXs are induced in 
hypoxic conditions in the primary tumour. Released in 
the circulation, LOXs travel to the bone where they impair 
osteoblast/osteoclast activity. LOXs cause increased bone 
resorption, by inhibiting osteoblast activity and increasing 
osteoclastogenesis. In this LOX-regulated environment, 
where pre-metastatic osteolytic lesions are formed, bone 
colonisation by breast cancer cells takes place (Cox et al. 
2015, Sousa & Maatta 2016).
Figure 1
Vicious cycle and dormancy. Bone is a favourite site for metastatic breast cancer. Tumour cells arriving in bone undergo dormancy. Osteoclasts and 
osteoblasts secrete factors to maintain bone homeostasis (factors released by osteoblasts and osteoclasts are indicated in orange and purple, 
respectively). Bone remodelling cytokines stimulate tumour cells that, after homing in bone, have entered a dormant state. Simultaneously, tumour cells 
produce factors (in grey) that stimulate further osteoblasts and osteoclasts activity, resulting in awakening cancer cells with the formation of overt bone 
metastases and altered bone turnover. This vicious cycle leads to enhanced tumour cell proliferation and aggressiveness, increased osteoclast number 
and activity and decreased osteoblast number and function, resulting in osteolytic bone metastases. We hypothesise that IL-1B is a putative factor 
exchanged between tumour cells, osteoblasts and osteoclasts, and a trigger for tumour cells awakening from dormancy and formation of bone 
metastasis.
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The activity of osteoblasts on bone is directly linked 
with the maintenance of breast cancer cell dormancy 
in this site. We recently showed that ovariectomy-
induced increase in osteoclast activity and bone turnover 
stimulates metastatic breast cancer cells to exit from their 
dormant state and start proliferating. When osteoclast 
activity was reduced in this ovariectomy model using the 
RANKL/RANK inhibitor, osteoprotegerin (OPG), breast 
cancer cells disseminated into bone were unable to 
proliferate into overt metastases and remained in a 
dormant state. (Ottewell et al. 2015). A link between IL-1B 
and OPG has been recently found in breast cancer primary 
tumour development and metastasis and will be discussed 
later in this review.
Amongst other cell types present in the bone, 
osteocytes are considered to play pivotal functions in 
maintaining the balance between osteoclast and osteoblast 
activity during bone remodelling, by creating a multi-
functional syncytium through the bone. Osteocytes are 
terminally differentiated cells derived from the osteoblast 
lineage. Osteoblasts are surrounded by their released 
extracellular matrix that forms the osteoid, constituted 
mainly by collagen I. Mature osteoblasts that localise in 
the osteoid are pre-osteocytes. During cell maturation, 
the osteoid mineralise and cells that are embedded in it 
are referred as osteocytes (Prideaux et al. 2016). In cancer 
biology, osteocytes have recently been described as playing 
anti-cancer functions. Osteocytes use connexin 43 (Cx43) 
hemichannels in an intrinsic self-defense mechanism 
against breast cancer cells colonizing the bone. Cx43 is used 
by osteocytes to allow intra- and extra-cellular passage of 
small molecules. Upon bisphosphonate treatment, Cx43 
hemichannel opening results in anchorage-independent 
growth, migration and invasion inhibition of human 
breast cancer cells. Cx43-osteocyte-specific knock-
out mice and osteocyte-specific transgenic mice with 
impaired Cx43 gap junctions and hemichannels displayed 
enhanced tumour growth, limiting the anti-tumour effect 
of bisphosphonate (ZOL) treatment. Release of ATP from 
Cx43 hemichannels in osteocytes was found to mediate 
anti-cancer functions (Zhou  et  al. 2016). Despite this 
evidence suggesting an anti-tumour function exerted by 
osteocytes through Cx43, in vitro studies have shown that 
osteocytes might also play pro-tumour functions, when 
different breast and prostate cancer cell lines are used. 
Indeed, breast cancer cell lines treated with conditioned 
medium from osteocytes displayed either increased or 
decreased invasion and chemotaxis (Cui  et  al. 2016). 
In addition, divergent roles of ATP and adenosine released 
by osteocytes on breast cancer cells support the dual role 
of this bone cell type on breast cancer bone metastases 
(Zhou et al. 2015).
ATP has been identified in the conditioned media of 
alendronate-treated osteocytes as a factor responsible for 
breast cancer cell migration inhibition. ATP exerts anti-
cancer functions by activating purinergic P2X7 receptor 
on breast cancer cells. Use of ATP antagonist (oxidised ATP) 
or P2X7 knockdown results in reduced cancer inhibitory 
functions associated with ATP, whereas the use of BzATP 
agonist results in breast cancer migration inhibition in 
vitro. In addition, different ATP dosages correlate with 
pro- or anti-tumour function. In particular, low dosage 
of ATP inhibits breast cancer cell migration, whereas 
high dosage enhances breast cancer cell migration. In 
the same study, Zhou and colleagues showed that ATP 
significantly delays breast cancer primary tumour growth 
in a xenograft model. Finally, breast cancer growth in 
bone was also reduced in vivo upon treatment with a non-
hydrolysable ATP (ATPγS). Interestingly, upon binding to 
P2X7R, ATP mediates NLRP3 inflammasome-dependent 
IL-1B secretion (Karmakar  et al. 2016). Considering that 
IL-1B is a prognostic marker for breast cancer disease 
progression, it is puzzling to define a pro- or anti-tumour 
function for the energy-carrying molecule.
Alongside bone, the adipose tissue also presents 
support to breast cancer metastasis in this secondary 
site. During aging, adipose tissue increases in bone and, 
simultaneously, enhanced breast cancer metastasis can 
be observed. Breast cancer cells establish contacts with 
adipocytes when in co-culture with cancellous bone 
fragments of human origin and increase their migratory 
properties. The analysis of conditioned medium derived 
from human bone tissue identified high levels of IL-1B 
(Templeton et al. 2015).
More recent advances in the understanding of 
tumour–microenvironment interactions have elucidated 
the crucial role of the immune system in either supporting 
or inhibiting cancer progression. Tumour-associated 
macrophages (TAMs) have been found to infiltrate primary 
breast cancer. Previously classified in M1 (classically 
activated macrophages with anti-cancer functions) 
and M2 (alternatively activated macrophages with pro-
tumour functions), macrophages are now grouped into 
four categories: M1 (IFNy/LPS), involved in inflammation, 
microbial killing and anti-tumour functions; M2a 
(IL4/IL13) involved in allergic reactions, intracellular 
parasite killing and matrix remodelling; M2b 
(immunocomplexes) associated with immunoregulation 
and suppression of inflammation and M2c (IL10) 
responsible for Treg stimulation, immunosuppression 
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and matrix remodelling. TAMs generally have an 
M2 phenotype. In breast cancer, high density of 
TAMs associates with poor prognosis. TAMs support 
tumour angiogenesis, invasion by remodelling of 
the tumour extracellular matrix, mechanisms of 
immune evasion, infiltration of immunosuppressive 
leukocytes and activation of breast cancer stem cells 
(as reviewed by Choi  et  al. 2018). Moreover, in the 
context of tumour relapse after chemotherapy, MRC1hi, 
CXCR4hi, Tie2hi VEGFA+ macrophages have been identified 
as tumour-supporting M2 macrophages localising in 
perivascular areas where CXCL12 is expressed. These 
are perivascular macrophages that stimulate tumour 
relapse after chemotherapy (Hughes et al. 2015). Tumour-
infiltrating macrophages can be derived from circulating 
monocytes (formed in the bone marrow) or tissue-
resident macrophages (embryonal origin). The role of 
bone marrow-resident macrophages (OsteoMacs) is 
currently under investigation. So far, indirect evidence 
allows to speculate that metalloprotease (MMP9) and 
macrophage colony-stimulating factor (M-CSF) levels in 
breast cancer cells (MDA-MB-231) correlate with TAM 
infiltration and OsteoMac polarization (Sousa & Maatta 
2016). Monocytes and macrophages can differentiate 
into osteoclasts by the combination of RANKL and 
M-CSF. Additional stimulation with cytokines involved 
in M1/M2 polarisation has been found to either promote 
or impair macrophage differentiation into osteoclasts 
(Jeganathan  et  al. 2014). Therefore, understanding the 
balance between macrophage and osteoclast polarisation 
in bone could provide new insights in breast cancer bone 
metastases.
Interestingly, breast cancer cells have been found 
to modulate the haematopoietic stem cell niche by 
modulating the CXCL12–CXCR4 signalling axis. In 
particular, CXCL12 levels in bone marrow-derived 
mesenchymal stromal cells were found to be lower upon 
treatment with medium derived from breast cancer cells 
or in co-culture conditions. CXCL12 downregulation 
affected HSPCs migration towards MSC/cancer cells 
co-culture or conditioned medium (Wobus  et  al. 2015). 
Furthermore, the cross-talk between MSCs and cancer cells 
relates to CDH1 (E-cadherin) and IL-1B levels. High CDH1 
and low IL-1B in cancer cells induce MSC organization 
into a niche like formation, dependent on direct cell–cell 
contact, in vitro (Al-toub et al. 2015).
It has been hypothesised that metastatic cancer cells 
compete with HSCs to colonise their niche in bone. 
Evidence from prostate cancer shows that CXCL12-CXCR4 
signalling is involved in the niche colonisation by 
tumour cells and competition with HSCs. Once in bone, 
dormant tumour cells are exposed to a microenvironment 
that generally maintains HSCs in a quiescent state. This 
microenvironment is hypoxic and populated by stromal 
cells that produce anti-apoptotic and pro-survival signals 
(Ren  et  al. 2015). Therefore, tumour–HSC interaction 
mainly contributes to tumour dormancy.
IL-1B signalling and breast cancer
IL-1B signalling
The IL-1 type cytokine family comprises seven molecules 
with agonist functions, including IL-1B and IL-1A, three 
receptor antagonists and one anti-inflammatory cytokine. 
Evolution studies have shown that, starting from fish, 
vertebrates have a single IL-1 gene (Ogryzko et al. 2014). 
IL-1 cytokines bind to IL-1R receptors. There are eleven 
IL-1R receptors. IL-1B and IL-1A are encoded by distinct 
genes and bind both to IL-1R1, found on nearly every cell 
and IL-1R2 (Garlanda et al. 2013). IL-1A is also known as 
alarmin, and it can be found in homeostatic conditions. 
IL-1A precursor is constitutively present in several 
epithelial layers, and it is already active when released 
upon cell necrosis. IL-1A mediates the early phases of sterile 
inflammation by rapidly inducing a cascade of several 
cytokines and chemokines. Different from IL-1A, IL-1B 
is not present in homeostatic conditions. IL-1B plays its 
main role as ‘gatekeeper’ of inflammation. IL-1B is mainly 
produced by blood monocytes, tissue macrophages, skin 
dendritic cells and brain microglia (Garlanda et al. 2013). 
IL-1B synthesis occurs upon stimulation by pattern-
associated molecular patterns (PAMPs), whereas its 
activation is linked to secondary stimuli, such as damage-
associated molecular patterns (DAMPs), in the presence 
of invading pathogens and upon sterile danger signals 
(Brough  et  al. 2011, Baroja-Mazo  et  al. 2014). IL-1B is 
processed by the inflammasome, a multi-protein complex 
activated via non-obese diabetic (NOD)-like receptor (NLR) 
family, pyrin domain-containing proteins (NLRPs) and 
required for the activation of caspase 1, needed for IL-1B 
cleavage and activation (Miller et al. 1993, Li et al. 1995) 
(Fig. 2). Caspase-1-mediated pyroptosis is a lytic form of 
cell death and an innate immune effector mechanism. 
During inflammation, after caspase-1-mediated cleavage 
and activation, IL-1B is released in a still poorly understood 
‘unconventional’ secretory manner (Vince & Silke 2016). 
A simple hypothesis suggests that activated IL-1B is 
passively released after caspase 1-induced pyroptosis, 
underlining the link between cell death and inflammation. 
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In addition, the role of gasdermins D (GSDMD) proteins 
in inducing pyroptosis, upon inflammatory caspase 
cleavage, has been recently described and suggested that 
their pore-forming function during pyroptosis is needed 
for IL-1B secretion after maturation (Ding  et  al. 2016). 
As GSDMs play an important role in the induction of 
pyroptosis, this type of cell death has been renamed as 
GSDM-mediated programmed necrosis, characterised by 
osmolytic potential disruption and consequent cell lysis 
(Shi et al. 2017). The formation of GSDM-mediated pores 
allows IL-1B secretion even when a cell is still intact and 
functional, restricting the passage of larger molecules 
and organelles. Importantly, after pore formation, cells 
can shut down the inflammasome, allowing IL-1B release 
while preventing pyroptosis, therefore explaining how 
IL-1B secretion can occur even without cell death (Kovacs 
& Miao 2017). Pyroptosis also occurs in non-immune 
cells, where it is characterised by the activation of other 
caspases (11/4/5), which do not cleave IL-1B (Shi et  al. 
2017). Alongside caspase-1-mediated pyroptosis, active 
release of IL-1B has also been described, via secretory 
lysosomes, multivesicular bodies and direct micro-
vesicular shedding (Vince & Silke 2016). Once cleaved and 
released, IL-1B binds to its correspondent receptor, IL-1R1, 
which can also be recognised by IL-1A and the antagonist 
(IL-1RA). However, different from IL-1A and IL-1B, IL-1RA 
does not trigger downstream signalling activation upon 
binding to IL-1R1 (Weber  et  al. 2010). Together with 
IL-1RA, IL-1R2 (decoy receptor) and the ‘shed’ domains 
of each extracellular IL-1 receptor chains function as 
negative regulators of IL-1 signalling. IL-1R1 and IL-1R2 
share high similarity and their extracellular domains 
are members of the immunoglobulin superfamily, each 
comprising three IgG-like domains. The extracellular 
domains of IL-1R1 and IL-1R2 can also be found as 
soluble forms. IL-1R has a single transmembrane domain 
and a cytoplasmic domain and is the main receptor that 
transduces downstream signalling (Dinarello 1997). IL-1 
signalling activation occurs upon binding to the IL-1R1 
receptor and consequent conformational change of the 
extracellular domain. Further recruitment of IL-1RacP 
(IL-1R-associated protein) and activation of cytosolic 
Toll- and IL-1R-like domains results in the recruitment of 
Myd88 (myeloid differentiation primary response gene-
88) and IRAK4 (interleukin-1 receptor associated kinase-4). 
IRAK4 undergoes autophosphorylation and causes the 
phosphorylation of IRAK1 and IRAK2, with following 
recruitment of TRAF6 (TNF receptor-associated factor). 
IRAK1/2 and TRAF6 dissociate from the receptor complex 
and activate nuclear factor kappa-light-chain-enhancer of 
Figure 2
IL-1B signalling. IL-1B is produced as pro-peptide and activated by cleavage upon cell stimulation by PAMPs and DAMPs, as response mechanism to 
invading pathogens and cellular stress caused by sterile danger signals. IL-1B is functionally activated upon cleavage by caspase-1, which in turn, is 
activated by the NLRP3 inflammasome complex. After cleavage and activation, IL-1B is released by the cell, according to a poorly understood mechanism 
that comprehends both active and passive processes, including pyroptosis. Once released, IL-1B activates IL-1R1 receptor. Downstream signalling 
activation through Myd88, IRAKs and TRAF6 leads to NFKB-mediated transcription of pro-inflammatory cytokines and initiation of inflammation.
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activated B cells (NFkB). Once in the nucleus NFkB acts 
as a transcription factor for inflammatory genes, such as 
IL-6, IL-8, MCP-1 and cyclooxygenase-2 (COX-2) (Weber 
et al. 2010) (Fig. 2).
IL-1 signalling in primary tumours and its role in 
initiating metastasis
Human cancerous breast tissue expresses IL-1B. Recent 
evidence from our group has shown that breast cancer 
cells with increased ability to metastasise in bone 
(MDA-IV) display higher IL-1B expression, compared to 
its correspondent parental line, suggesting that IL-1B 
expression correlates with enhanced metastatic potential 
(Nutter et al. 2014).
A positive correlation between IL-1B expression, OPG 
and CCL2 has been found in human breast cancer genome-
wide mRNA expression array. OPG belongs to the TNF 
receptor superfamily, and it functions as a decoy receptor 
during bone resorption and affects TRAIL-mediated 
apoptosis. Inhibition of OPG in breast cancer cell lines 
showed reduced invasion and metastasis. In particular, 
IL-1B upregulates OPG via p38 and p42/22 MAPK 
signalling pathway and induces OPG secretion, which also 
associates with macrophage infiltration in primary breast 
tumours. Co-culture of IL-1B-secreting macrophages and 
breast cancer cells results in enhanced OPG secreted by 
tumour cells (Chung  et  al. 2017). Taken together, these 
data suggest a role of IL-1B and OPG in mediating breast 
cancer metastasis and inflammation. Data shown above 
suggest that OPG has the potential to act as both pro- and 
anti-tumour molecule dependent on whether the tumour 
is at its primary or metastatic site and if OPG is produced 
by tumour cells or by the cells in the microenvironment. 
Whether anti-tumour effects are specific to the bone 
microenvironment remain to be elucidated. OPG, mainly 
expressed by osteoblasts, is a decoy receptor and is a 
natural inhibitor of osteoclastogenesis (through inhibition 
of RANKL/RANK signalling) (Boyce & Xing 2008, Le Pape 
et al. 2016). This potentially explains its anti-tumour effect 
in bone. In addition to playing a role in tumour growth, 
IL-1B has been reported to control tumour invasion. 
In vitro evidence from MCF7 breast cancer cells suggests 
that this may, in part, be due to, IL-1B-regulating breast 
cancer cell invasion by stimulating production of MMP-9 
via focal adhesion kinase 1 FAK and the proto-oncogene 
tyrosine-protein kinase Src (Mon et al. 2017).
IL-1B and IL-1A may both play roles in tumour 
formation and progression to metastasis. IL-1B has 
been linked with poor prognosis in breast cancer 
(Nutter et  al. 2014), whereas tumour-induced IL-1A has 
been linked to CCL22 production by tumour-infiltrating 
immune cells. CCL22 is known to induce the recruitment 
of T regulatory (Treg) cells. Inhibition of IL-1R1 signalling 
using Anakinra has been found to impair Treg migration 
(Wiedemann et al. 2016). In the same study, the authors 
also showed that as a result of silencing IL-1A in pancreatic 
tumour cells (PaTu), CCL22 production was inhibited in 
PBMC, whereas inhibition of IL-1A or IL-1B in mammary 
4T1 cancer cell line resulted in impaired CCL22 production 
in splenocytes. In addition to promoting tumour 
progression, by controlling Treg recruitment via CCL22 
signalling, however, IL-1A mediated IL-1R1 signalling 
has also been reported to have anti-tumour functions. 
In particular, using a spontaneous murine mammary 
tumour model (MMTV-PyMT), Dagenais and colleagues 
have shown that IL-1R1 signalling suppresses mammary 
tumour cell proliferation early in tumourigenesis and 
reduces breast cancer outgrowth and metastasis in the 
lungs. High primary tumour burden was found in both 
IL-1R1 −/− and IL-1A −/− mice, and this phenotype 
was independent of caspase-1/-11 (Dagenais et al. 2017). 
Hence, IL-R1 signalling could have both pro- and anti-
tumour functions and it is possible that IL-1A and IL-1B 
may exert opposite functions in breast cancer progression.
The murine spontaneous mammary tumour model 
MMTV-PyMT has been employed to investigate the role of 
IL-1 and the inflammasome in primary mammary tumour 
growth and pulmonary metastasis, alongside allograft and 
xenograft models of breast cancer. For this purpose, mice 
lacking functional caspase-1 and NLRP3 in combination 
with pharmacological treatment to inhibit IL-1R were 
employed. Inhibition of the inflammasome and IL-1 
signalling resulted in reduced primary tumour growth, lung 
metastasis and myeloid cell infiltration (Guo et al. 2016).
The data above fit with our recent findings in which 
we showed that IL-1 associates with primary tumour 
development of human mammary tumours in vivo. 
Pharmacological inhibition of IL-1R with Anakinra 
before subcutaneous injection of either triple-negative 
MDA-231-IV or ER+ve MCF-7 cells significantly reduced 
tumour formation, whereas treatment of established 
tumours with Anakinra significantly reduced tumour cell 
proliferation (Fig.  3). These data suggest that inhibition 
of IL-1R signalling impairs breast cancer progression from 
both ER-ve and ER+ve tumours (Holen et al. 2016a).
IL-1B has been shown to have profound effects 
on tumour growth and metastasis in tumour types 
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other than breast cancer, including melanoma. A 
reduction of local tumours or lung metastasis was 
found in mice lacking functional IL-1R signalling 
(IL-1B KO), together with diminished tumour 
angiogenesis. Similar results on angiogenesis were 
also found upon IL-1R pharmacological inhibition. 
IL-1A KO mice also displayed a reduction in melanoma 
growth and angiogenesis compared to WT animals, but 
the effect was less evident when compared to IL-1B KO 
mice, suggesting a major role of IL-1B. The findings 
could be extended to mammary and prostate cancer 
models (Voronov et al. 2003).
IL-1B signalling in tumour-induced angiogenesis
Tumour angiogenesis is a hallmark of cancer and IL-1 is 
a strong endothelial cell (EC) activator. IL-1 enhances 
pro-inflammatory responses, angiogenesis, growth rate, 
migration, morphological changes, contact inhibition 
and permeability of ECs. IL-1B upregulates VEGF and its 
correspondent receptor on ECs and via IL-1R1 causes EC 
migration and tube formation by activating p38-MAPK 
and MAPK-activated protein kinase 2. Moreover, IL-1 has 
been described to synergise with VEGF and overlapping 
gene signatures have been identified in ECs, particularly 
for genes involved in cell growth and inflammation. In a 
matrigel model, abrogation of rVEGF or rIL-1B resulted 
in an abolished angiogenic response. Administration of 
rVEGF to mice with impaired IL-1B signalling resulted 
in reduced neo-angiogenic response in matrigel plugs 
(Carmi et al. 2013). There is considerable interest in using 
anti-angiogenic therapy; however, the results from clinical 
trials have been disappointing due to tumours rapidly 
developing resistance mechanisms to these drugs. The 
tumour microenvironment plays a large role in resistance 
to anti-angiogenic drugs with immune cells being a 
predominant source of angiogenic factors. Consequently, 
there are now a multitude of studies looking at the effect 
of combinatorial treatments to block angiogenesis as well 
as to modify immune cell response to improve the efficacy 
of anti-angiogenic therapy. Inhibition of IL-1B impairs 
the recruitment of immune cells at cancerous sites, 
limiting the production of pro-angiogenic molecules. 
IL-1Ra has been found to inhibit the angiogenic response, 
concomitantly inhibiting tumour progression. We 
recently showed that IL-1R1 antagonist Anakinra reduces 
the number of microvessels in sub-cutaneous breast 
tumours and bone metastases caused by the osteotrophic 
triple-negative breast cancer cell line MDA-MB-231-IV, 
after both a preventative and treatment strategy (Fig. 3) 
(Holen et al. 2016a). Therefore, IL-1 signalling inhibition 
in combination with anti-angiogenic therapies could 
represent the way forward to limit tumour progression 
(Voronov et al. 2003).
Figure 3
IL-1 signalling in breast primary tumour and bone metastasis. IL-1 signalling controls breast cancer growth at both primary and bone metastatic sites. 
Osteotrophic breast cancer cells MDA-231-IV or ER+ breast tumour cells MCF-7 are implanted subcutaneously in BALB/c-nude mice to mimic primary 
tumour growth. IL-1 signalling inhibition using the receptor antagonist Anakinra results in reduced tumour growth as well as diminished tumour 
microvessel density. Upon i.v. injection, MDA-231-IV cells home to bone. Anakinra treatment affects metastatic breast cancer tumour growth, without 
altering the number of cells homing to this site, suggesting the involvement of IL-1 signalling in breast cancer dormancy in bone.
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IL-1B signalling in breast cancer and inflammation
IL-1B signalling and inflammation are strongly connected 
and inflammation plays a major role during cancer 
progression. In particular, the fine balance between IL-1B 
and IL-1Ra activity is important to control inflammation: 
IL-1B and IL1R1a overexpression results in an enhanced 
and reduced inflammatory state, respectively.
In bone inflammatory diseases like rheumatoid 
arthritis, enhanced inflammation and osteoclast 
differentiation and activation have been reported. In this 
condition, enhanced infiltration of macrophages, which 
are a primary source of pro-inflammatory cytokines, 
causes bone damage (Okano et al. 1996, Funk et al. 1998). 
In addition, IL-1B produced by macrophages and T cells 
increases osteoclastogenesis, by regulating osteoclast 
progenitors (Strand & Kavanaugh 2004). Because IL-1B 
regulates bone homeostasis and contributes to enhanced 
bone resorption upon inflammation, it is possible to 
speculate that in breast cancer metastasis, IL-1B alters 
bone turnover in favour of the vicious cycle (Fig. 1). The 
mechanism by which IL-1B produced by different cell 
types promotes metastasis is still under investigation.
Immune cells also play a pivotal role in cancer 
and inflammation. Mice lacking IL-1R display delayed 
myeloid-derived suppressor cell (MDSC) infiltration 
and reduced primary breast tumour development, a 
phenotype that is restored by IL6. Conversely, mice with 
a non-functional IL-1Ra display enhanced inflammation, 
characterised by a more rapid accumulation of MDSCs in 
breast tumour. This finding suggests that inflammation 
supports tumour progression by enhancing immune-
suppressive mechanisms (Bunt et al. 2007). In vitro studies 
have recently shown that primary breast cancer cells 
co-cultured with monocytes display increased IL-1B, IL8 
and MMPs (Espinoza-Sanchez et al. 2017), suggesting that 
inflammation and therefore the recruitment of immune 
cells support the development of breast cancer during 
the early stages. In addition, pro-inflammatory effects of 
IL-1B also promote metastasis: In a spontaneous in vivo 
model of breast cancer, tumour cells induce systemic 
inflammation by producing IL-1B, which stimulates 
IL-17 production by γδ T cells. Subsequently, IL-17 
drives the production of G-CSF that causes neutrophil 
expansion and polarization towards a CD8+ T cell-
suppressive phenotype via iNOS, enhancing immune 
suppression and distant metastases (lung and lymph 
nodes) (Coffelt et al. 2015). IL-1B is also involved in the 
mobilisation of MDSCs further promoting both primary 
and metastatic breast tumours (Karki et al. 2017).
Finally, NLRP3-IL-1B-IL1R signalling has been shown 
to control NK and T cells, by inhibiting their tumouricidal 
potential and inhibiting the anti-tumour effect of 
chemotherapeutic agents by inducing the secretion of 
IL17 by CD4+ T cells (Karki et al. 2017). The IL-1B-driven 
detrimental role of the inflammasome in cancer opposes 
to its protective role, mainly driven by IL-18, as reviewed 
in (Karki et al. 2017).
IL-1B in breast cancer bone metastasis
Expression of IL-1B by primary breast cancer cells strongly 
correlates with disease re-occurrence and future relapse 
in bone: In tissue arrays containing 150 primary tumour 
biopsies taken from patients newly diagnosed with stage 
II/III breast cancer enrolled onto the AZURE trial, 49% of 
patients with detectable IL-1B in their tumours experienced 
relapse compared with 7% of patients with IL-1B-negative 
tumours and 37% of patients with detectable IL-1B in their 
primary tumours developed bone metastasis compared 
with 5% of patients with IL-1B-negative tumours over 
an 84-month time period (Coleman  et  al. 2011). In 
addition, breast cancer cell lines that specifically home to 
and colonise mouse bone (MDA-IV) have been shown to 
express high levels of IL-1B (Nutter et al. 2014). We have 
recently shown that inhibiting IL-1R signalling, using 
the receptor antagonist Anakinra, results in decreased 
breast cancer bone metastases (Fig.  3). Administration 
of Anakinra before injection of tumour cells did not 
prevent numbers of tumour cells that arrived in the bone 
environment, but held these tumour cells in a dormant 
state, significantly inhibiting development of both micro-
metastases and overt metastases. When Anakinra was 
given 1 week after tumour cell inoculation these existing 
bone metastases ceased to grow, and this appeared to be the 
result of reduced proliferation and reduced angiogenesis, 
whereas apoptotic cell death remained unaltered. Because 
of the tight coupling between tumour cells and bone cells 
that occurs in bone metastases, the effects of IL-1B on the 
bone environment may also play important roles in this 
process. In tumour-naïve mice, a single dose of Anakinra 
reduces osteoclast and osteoblast activity in addition to 
causing a reduction in IL-1B and TNFa levels indicating 
that in addition to anti-tumour effects of Anakinra, this 
drug may also target bone cells thus reducing resorption 
and availability of bone-derived growth factors that can 
further stimulate tumour growth. These Anakinra-induced 
alterations to the bone environment were maintained 
following continuous administration of Anakinra for 
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>21  days, and this treatment did not cause significant 
effect on trabecular bone volume. Taken together, these 
data suggest that Anakinra could be re-purposed as a 
treatment of bone metastatic breast cancer (Holen et al. 
2016a).
As evidenced above, blocking IL-1R activity with 
Anakinra holds disseminated tumour cells in a dormant 
state in the bone environment. Recent in vitro data indicate 
that IL-1B and not IL-1A is the relevant cytokine linked 
to dormancy of breast cancer cells in this environment. 
Co-culture of a human breast cancer cell line, with 
suppressed ability to form metastases, with osteoblasts 
resulted in faster growth of breast cancer cells attached 
to the matrix made by the osteoblasts when stimulated 
with IL-1B and TNFa. Interestingly, the IL-1B and TNFa-
stimulated growth was suppressed when COX2 activity or 
PGE2 receptor were blocked, in line with data showing 
that IL-1B and TNFa activate the arachidonic acid pathway 
(Mark et al. 2001, Ono 2008, Sosnoski et al. 2015).
MSCs play a pivotal role in bone metastases as their 
niche overlaps with the cancer stem cell niche in this 
environment. How breast cancer cells, chemokines and 
cytokines, including IL-1B affect these cells may be a 
fundamental factor in determining whether tumour cells 
in bone are able to progress to overt metastases. Exposing 
MSCs to conditioned media derived from metastatic breast 
cancer cells resulted in increased levels of chemokines, 
such as CXCL1, 3, 5, 6, 8, CCL2 and CCL7. Importantly, 
chemokine expression was inhibited in MSCs exposed to 
conditioned media derived from metastatic breast cancer 
cells treated with NFKB inhibitor. Interestingly, amongst 
NFKB downstream targets, IL-1B has been identified as 
a major regulator of chemokine production in MSCs. 
IL-1B was present in the supernatant of metastatic breast 
cancer cells. When treated with IL-1B, MSCs were found 
to upregulate the same cytokines that were observed 
following exposure to cancer cell conditioned media. 
Inhibition of IL-1B in metastatic breast cancer cells 
resulted in no chemokine production by MSCs, whereas 
overexpression of IL-1B in non-metastatic breast cancer 
cells increased chemokine levels in MSCs. Therefore, 
IL-1B is a major candidate in driving the production of 
chemokines in the tumour microenvironment, which, in 
turn, sustain tumour development (Escobar et al. 2015).
Murine models of breast cancer bone 
metastasis for investigating IL-1B signalling
The majority of mouse models that are used to study bone 
metastasis involve injecting MDA-MB-231 cells (breast) 
or PC3 (prostate) and their bone-homing derivatives 
directly into the left cardiac ventricle from where the 
cells become disseminated in the skeleton (Ottewell et al. 
2010, 2014a,b, Nutter et al. 2014). Although this method 
does not mimic the early stages of the metastatic process 
consisting of growth at the primary site and dissemination 
into the circulation, human breast cancer cell lines do not 
spontaneously metastasise from the fat pad to the mouse 
skeleton without oestradiol supplementation. Although 
oestrogen receptor-positive breast cancer cell lines, MCF7 
and T47D reliably metastasise from mouse mammary fat 
pads to mouse long bones in ~90% of animals when mice 
are supplemented with oestradiol, it is hypothesised that 
metastasis to bone is driven by the bone anabolic effects 
of oestradiol (Holen  et  al. 2016b), as IL-1B also affects 
bone turnover data obtained using these model systems 
would need to be interpreted with this in mind (Holen 
et  al. 2016a). For more basic experiments designed to 
investigate tumour growth in bone and tumour cell–bone 
cell interactions, it is possible to inject most cancer cell 
lines directly into the tibiae or femur. It must be noted, 
however, that this method does not model tumour cell 
dissemination into the bone metastatic niche, tumour 
cells grow randomly within the marrow cavity from 
direct injection into bone and bone healing occurs in 
conjunction with tumour induced lesion formation, 
complicating data analysis (Wright et al. 2016)
The growth of human cancer cells in mice requires the 
use of immunocompromised mice negating the role of the 
immune system. This may be especially important when 
studying the effects of a pro-inflammatory cytokine such as 
IL-1B. Intra-cardiac or intra-mammary injection of mouse 
mammary 4T1 cells results in metastasis to lung, liver, brain 
and bone and bone homed derivatives including 4T1.1 have 
increased bone-homing capacities. Many researchers report 
increased metastasis following removal of the mammary 
tumour (Francia et al. 2011). The use of syngeneic models is 
an excellent tool to study the interaction between tumour 
cells and the microenvironment primarily because these 
animals have a fully competent immune system.
The use of breast cancer cell lines to model cancer 
development and progression has been heavily criticised 
due to these cells having been cultured in the laboratory for 
numbers of years leading to culture adaptation and loss of 
heterogeneity. This has led to the development of mouse 
models of metastasis utilising patient-derived tumours. 
Surgical implantation of patient-derived xenografts 
(PDXs) orthotopically into mice has been successfully 
used to study bone metastasis from prostate, breast and 
lung cancer, as well as other metastatic sites for different 
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cancer types (i.e. lymph node and liver metastasis for 
colon cancer and metastatic pancreatic, stomach, ovarian, 
bladder and kidney cancer) (Hoffman 1999). Tumour cells 
behave differently according to the microenvironment 
in which they are seeded. Orthotopic models offer 
significant advantages over subcutaneous models as they 
more accurately model interactions between tumour 
cells and organ-specific microenvironments, allowing 
to study the behaviour of human tumours in the tissue 
from which they originate. Environmental signals prime 
tumours in the primary site to metastasise to specific 
organs, therefore, in order to accurately study organ-
specific tropism of metastasis, orthotopic implantation of 
tumour cells may be necessary. However, bone metastasis 
from these models is rare and growth of patient-derived 
material requires oestradiol supplementation, and the 
bone anabolic effects of oestradiol need to be taken into 
account when interpreting data from these models.
Other PDX models have been developed to address 
different questions related to the biology of cancer. PDX 
allows to study intra- and inter-tumour heterogeneity 
and how this affects response to therapy. PDX models 
can be used to study primary or acquired resistance 
to drugs by engrafting patient-derived material that 
has been isolated from patients before or after therapy, 
respectively. Clinical trial-associated xenografts (CTAXs) 
are a form of PDX model that has the potential to be used 
in personalised medicine, as biopsies taken from patients 
during clinical trials, at different stages of treatment 
and disease progression. Generally, PDX models use 
immunocompromised animals to allow engraftment of 
human tissues. Originally, patient-derived xenografts to 
study metastatic breast cancer were developed in nude 
mice (Fu et al. 1993), whereas today there is a conscious 
move to using murine models of NOD SCID gamma mice, 
which have been engrafted with human immune cells. 
In this model, total peripheral blood or bone marrow from 
healthy donors or patients is injected into the tail vein of 
young animals in order to consider the contribution of 
the immune system in tumour progression.
There are a number of mouse models that can be used 
to study different stages of the bone metastatic process from 
different tumour types. Each model has its pros and cons 
and data obtained from these models should be interpreted 
with specific limitations in mind. There is an ongoing effort 
to make more clinically relevant mouse models of bone 
metastasis and a complete review on how to set up and 
utilise these models can be found in Wright et al. (2016).
Pharmacological inhibition of IL-1 signalling
IL-1B is an inflammatory molecule and targeted therapies 
have been developed to treat chronic inflammation and 
auto-inflammatory diseases. IL-1 signalling inhibition 
was first achieved using Anakinra, a recombinant form 
of the naturally occurring IL-1 receptor antagonist. 
Originally introduced in 2001 to treat rheumatoid arthritis 
(Dinarello et al. 2012), Anakinra has been recently proposed 
as a potential treatment for pericarditis and cardiovascular 
complications occurring during diabetes mellitus 
(Peiro  et  al. 2017). It is currently clinically indicated for 
the treatment of inherited auto-inflammatory diseases 
associated with non-functional NLRP3 and ILRN cryopirin-
associated periodic syndromes (CAPS) (Jesus & Goldbach-
Mansky 2014). Alongside Anakinra, Rilonacept (soluble 
decoy receptor) and Ilaris (or Canakinumab, a neutralizing 
anti-IL-1B IgG1 antibody) are the drugs currently used in the 
clinical practice to target the IL-1 signalling pathway (Peiro 
et al. 2017). As shown in Table 1, Anakinra is currently in 
clinical trials for metastatic breast cancer (NCT01802970), 
metastatic colorectal cancer (NCT02090101), pancreatic 
adenocarcinoma (NCT02550327), multiple myeloma and 
Table 1 Clinical trials involving the use of Anakinra and Ilaris for the treatment of different cancer types.
Treatment Cancer type Clinical trial identifier Clinical trial phase
Anakinra and standard of care Metastatic breast cancer NCT01802970 Phase I
Anakinra and Bevacizumab Metastatic colorectal cancer NCT02090101 Phase II
Gemcitabine, Nab-Paclitaxel, Cisplatin and 
Anakinra
Pancreatic adenocarcinoma NCT02550327 Early Phase I
Anakinra alone or with Dexamethasone Multiple myeloma NCT00635154 Phase II
Plasma cell neoplasm
Anakinra or Denosumab and Everolimus Advanced cancers NCT01624766 Phase I
Lenalidomide and Dexamethasone with or 
without Anakinra
Indolent plasma cell myeloma NCT02492750 Phase I, followed 
by Phase IIPlasma cell myeloma 
Smoldering plasma cell myeloma
PDR001 in combination with CJM112, EGF816, 
Ilaris (Canakinumab) or Mekinist 
(Trametinib)
Colorectal cancer, triple-negative 
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plasma cell neoplasm (NCT00635154). It is used alone or in 
combination with chemotherapeutic agents (Gemcitabine, 
Nab-Paclitaxel, Cisplatin) (NCT02550327), anti-
resorptive agents (Denosumab, anti-RANKL monoclonal 
antibody) (NCT01624766), mTOR inhibitor (Everolimus) 
(NCT01624766) and Lenalidomide and Dexamethasone 
(NCT02492750) (early stages multiple myeloma). A 
clinical trial for colorectal cancer, triple-negative breast 
cancer, NSCLC and adenocarcinoma in Phase 1 is currently 
recruiting participants to test the checkpoint inhibitor 
PDR001 in combination with other immunomodulatory 
agents, including Ilaris (NCT02900664). The results of 
these clinical trials will be awaited with interests and they 
will provide valuable information on the use of Anakinra 
and Ilaris used alone or in combination with other 
therapeutic regimes to treat cancer patients.
Conclusions and future directions
Bone is a preferential metastatic site for breast cancer. 
IL-1B has been identified as biomarker that can be used 
to predict which breast cancer patients are likely to 
experience relapse in bone. In vitro studies have suggested 
so far that IL-1B correlates with increased aggressiveness 
of breast cancer cell lines. Although in vivo studies are in 
their infancy, those that have been carried out confirm 
these findings. In particular, we have shown that IL-1 
signalling is linked to breast cancer metastasis specifically 
to bone. The inhibition of IL-1R1 and reduced bone 
metastasis in our mouse model shows the role of this 
signalling axis in breast cancer metastasis to bone, but 
further studies are needed to elucidate whether IL-1B 
and/or IL-1A are primarily involved in this process.
The combination of anti-angiogenic therapies and 
immune therapies represent a new strategy to treat 
tumours that develop resistance to standard of care 
treatments and/or anti-angiogenic therapy alone. Intra-
tumoural myeloid cells have been found to regulate 
responsiveness and resistance to anti-angiogenic 
therapies (Rivera  et  al. 2015). IL-1B is the gatekeeper of 
inflammation. It is produced mainly by immune cells, 
challenged by invading pathogens and danger signals and 
has been found to exert angiogenic functions. Therefore, 
inhibiting IL-1B signalling is a potential new therapeutic 
strategy to simultaneously block angiogenesis and dampen 
inflammation, impairing breast cancer bone metastasis. 
The availability of safe and approved therapeutic strategies 
targeting IL-1 signalling such as Anakinra and Ilaris could 
facilitate the treatment of patients affected by breast 
cancer-driven bone disease.
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